All Stories

  1. International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative
  2. Plasma biomarkers in neuropsychiatric syndromes: A narrative review
  3. Disentangling the Clinical and Neuroimaging Spectrum of Neuronal α-Synucleinopathies
  4. Leveraging multiomic approaches to elucidate mechanisms of heterogeneity in Alzheimer's disease: Neuropsychiatric symptoms, co‐pathologies, and sex differences
  5. Message From the Editors to Our Reviewers
  6. International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative
  7. APOE -mediated associations of promoter variants of GRIN1 and GRIN2B with behavioral symptoms and age at onset of Alzheimer’s disease dementia
  8. Understanding barriers and optimizing socio‐cognitive assessment in the diagnosis of neurocognitive disorders
  9. Analysis and interpretation of inflammatory fluid markers in Alzheimer’s disease: a roadmap for standardization
  10. Message From the Editors to Our Reviewers
  11. The problem of multiple adjustments in the assessment of minimal clinically important differences
  12. Biomarkers in Clinical Trials of Alzheimer Disease: An Overview
  13. Associations between selected genetic variants and lipid profile variability in response to statins in Alzheimer’s disease: a prospective observational study
  14. List of Reviewers
  15. Anthropometric and Demographic Features Affect the Interpretation of Cerebrospinal Fluid Biomarkers in Patients with Different Dementia Syndromes and Cognitively Healthy Adults
  16. Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease
  17. Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease
  18. Assessing Independence in Activities of Daily Living and Quality of Life in Patients with Dementia with Lewy Bodies
  19. Message From the Editors to Our Reviewers
  20. Shedding Light on the Effects of Blood Pressure on Cognitive Decline and Dementia Risk by Way of Neurobiological Evidence
  21. Biofluid Activity and Levels of the Angiotensin-converting Enzyme Are Surrogates for Diverse Cerebrospinal Fluid Amyloid-beta Effects in Dementia with Lewy Bodies and Alzheimer’s Dementia (P6-9.001)
  22. Message From the Editors to Our Reviewers
  23. Acknowledgement to Reviewers
  24. List of Reviewers
  25. GRIN2B genotypes and APOE haplotypes affect the age at onset of Alzheimer’s dementia as well as variations in dementia staging according to the use of Memantine
  26. Differential performance of cerebrospinal fluid biomarker ratios and formulas to discriminate dementia with Lewy bodies from Alzheimer’s dementia and cognitively healthy people reflects high level of amyloidosis across dementia syndromes
  27. Biofluid activity and levels of the angiotensin‐converting enzyme may translate into distinct neuropsychiatric symptoms associated with cerebrospinal fluid amyloid‐beta effects and tauopathy in dementia with Lewy bodies and Alzheimer’s dementia
  28. Disparities in neuropsychiatric symptom clusters across dementia diagnoses within Lewy body dementia syndromes and Alzheimer’s dementia
  29. Variations in metabolic risk factors for dementia do not affect APOE‐mediated cognitive or functional decline in patients with Alzheimer’s disease from São Paulo, Brazil
  30. Pitfalls and biases in neuroepidemiological studies of COVID-19 and the nervous system: a critical appraisal of the current evidence and future directions
  31. Pharmacogenetics of angiotensin modulators according to APOE-ε4 alleles and the ACE insertion/deletion polymorphism in Alzheimer’s disease
  32. Message From the Editors to Our Reviewers
  33. Looking Behind the Curtain: Patient Stratification According to Genetic or Demographic Factors May Yield Unexpected Results in Studies of Neurodegenerative Diseases
  34. Effects of the DICE Method to Improve Timely Recognition and Treatment of Neuropsychiatric Symptoms in Early Alzheimer’s Disease at the Memory Clinic: The BEAT-IT Study
  35. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer’s disease
  36. Lifestyle and pharmacological interventions in South America: Potential barriers for recruitment, implementation, and effectiveness
  37. Acknowledgement to Reviewers
  38. Message From the Editors to Our Reviewers
  39. List of Reviewers
  40. The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All
  41. Acknowledgement to Referees
  42. Acknowledgement
  43. APOE ε4 Carrier Status as Mediator of Effects of Psychotropic Drugs on Clinical Changes in Patients With Alzheimer’s Disease
  44. Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
  45. Message From the Editors to Our Reviewers
  46. Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer’s Disease
  47. New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
  48. The Viability of Treatment Conditioned to the Pathophysiology of Alzheimer’s Disease
  49. Vascular cognitive impairment and dementia: An early career researcher perspective
  50. Message From the Editors to Our Reviewers
  51. List of Reviewers
  52. Acknowledgement
  53. Reviewer Acknowledgement, 2021
  54. Message From the Editors to Our Reviewers
  55. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer’s Disease and Cognitively Healthy People
  56. Abstract Anne H Berman – incoming ISBM president
  57. Behavioural effects of the ACE insertion/deletion polymorphism in Alzheimer’s disease depend upon stratification according to APOE-ϵ4 carrier status
  58. Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe
  59. APOE-ɛ4-mediated correlates of cerebrospinal fluid biomarkers of amyloidosis and neurodegeneration with cognition and functionality in dementia with Lewy bodies compared with Alzheimer’s dementia and cognitively healthy people (49)
  60. Acknowledgements to Reviewers
  61. Swallowing in behavioral variant frontotemporal dementia
  62. Message From the Editors to Our Reviewers
  63. List of Reviewers
  64. Klüver‐Bucy syndrome due to stroke in the left temporal lobe
  65. Vascular cognitive impairment due to dilated perivascular spaces in putamen: Connections with the ventrolateral prefrontal cortex and neurological deficits
  66. Dementia in Latin America: Paving the way toward a regional action plan
  67. Correlates of neuropsychiatric and motor tests with language assessment in patients with Lewy body dementia
  68. Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer’s Disease
  69. Neuropsychiatric feature profiles of patients with Lewy body dementia
  70. Agitation and impulsivity in mid and late life as possible risk markers for incident dementia
  71. The impact of SARS‐CoV‐2 in dementia across Latin America: A call for an urgent regional plan and coordinated response
  72. Acknowledgments
  73. CEREBROSPINAL-FLUID-BASED BIOMARKER EVIDENCE OF AMYLOIDOGENESIS IN DEMENTIA WITH LEWY BODIES DEPENDS UPON APOE-ε4 CARRIER STATUS
  74. PRISON WITHOUT WALLS: A CASE REPORT OF SEMANTIC VARIANT PRIMARY PROGRESSIVE APHASIA
  75. GRIN2A GENOTYPES AND APOE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER’S DEMENTIA BUT NOT FUNCTIONAL OR COGNITIVE RESPONSE TO MEMANTINE
  76. FOOT CLEARANCE WHILE STEPPING-IN-PLACE AS A TOOL TO SALIENT COGNITIVE AND MOTOR OUTPUT DEFICITS IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A PRELIMINARY STUDY
  77. BEHAVIORAL CORRELATES OF CEREBROSPINAL FLUID BIOMARKERS ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  78. Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
  79. Acknowledgements to Reviewers
  80. Acknowledgments
  81. Influence of Socioeconomic Status and Stress Over Quality of Sleep: A Systematic Review
  82. Author Index
  83. Keyword Index
  84. Movement Disorders: Volume 33, Number S2, October 2018
  85. Abstracts
  86. Lifetime Risk Factors for Functional and Cognitive Outcomes in Patients with Alzheimer’s Disease
  87. GENETICALLY MEDIATED LIFETIME RISK FACTORS FOR COGNITIVE AND FUNCTIONAL DECLINE IN PATIENTS WITH ALZHEIMER’S DEMENTIA FROM SÃO PAULO, BRAZIL
  88. APOE-DEPENDENT PSYCHOTROPIC EFFECTS OVER CLINICAL CHANGES IN ALZHEIMER’S DISEASE DEMENTIA
  89. COGNITIVE AND FUNCTIONAL CORRELATES OF CEREBROSPINAL FLUID CONCENTRATIONS OF AMINOACIDS AND MONOAMINE METABOLITES ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  90. COGNITIVE CHANGES ARE PHARMACOGENETICALLY MEDIATED BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN PATIENTS WITH ALZHEIMER’S DISEASE DEMENTIA
  91. Behavioral correlates of cerebrospinal fluid concentrations of aminoacids and monoamine metabolites according to APOE-ɛ4 carrier status in dementia with Lewy bodies compared with Alzheimer’s dementia and cognitively healthy people (P4.190)
  92. Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
  93. Acknowledgement to reviewers
  94. Effects of APOE haplotypes and measures of cardiovascular risk over gender-dependent cognitive and functional changes in one year in Alzheimer's disease
  95. Acknowledgements to Reviewers
  96. ePresentation
  97. ePoster Session
  98. Author Index
  99. Issue Information
  100. Associations of cerebrovascular metabolism genotypes with neuropsychiatric symptoms and age at onset of Alzheimer’s disease dementia
  101. Longitudinal lipid profile variations and clinical change in Alzheimer's disease dementia
  102. Reviewers for International Journal of Stroke 2016
  103. Neurological impressions on the organization of language networks in the human brain
  104. GRIN1 GENOTYPES AND APOE GENE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER'S DISEASE DEMENTIA BUT NOT COGNITIVE OR FUNCTIONAL RESPONSE TO MEMANTINE
  105. EFFECTS OF APOE GENE HAPLOTYPES AND MEASURES OF CARDIOVASCULAR RISK OVER COGNITIVE AND FUNCTIONAL DECLINE IN ONE YEAR IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA
  106. MOTOR ASPECTS OF DAILY LIVING FOLLOW COGNITIVE AND FUNCTIONAL STATUS BUT NOT BEHAVIOURAL SYMPTOMS IN PATIENTS WITH LEWY BODY DEMENTIA SYNDROMES
  107. Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
  108. Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease
  109. Swallowing in primary progressive aphasia
  110. Predictors of Cognitive and Functional Decline in Patients With Alzheimer Disease Dementia From Brazil
  111. Associations of Blood Pressure with Functional and Cognitive Changes in Patients with Alzheimer's Disease
  112. The Controversial Influence of Cerebrovascular Risk Factors over Pathological Mechanisms of Late-Onset Alzheimer's Disease Dementia
  113. Risk factors for cognitive and functional change in one year in patients with Alzheimer's disease dementia from São Paulo, Brazil
  114. Correlations among cognitive and behavioural assessments in patients with dementia due to Alzheimer's disease
  115. Contrasts Between Patients With Lewy Body Dementia Syndromes and APOE-ε3/ε3 Patients With Late-onset Alzheimer Disease Dementia
  116. A patient with agrammatic primary progressive aphasia developing frontotemporal dementia
  117. Pharmacogenetics of cerebrovascular metabolism modulators in dementia due to Alzheimer’s disease
  118. Assessment of sleep satisfaction in patients with dementia due to Alzheimer’s disease
  119. Acknowledgements
  120. Is there correlation between cognition and functionality in severe dementia? The value of a performance-based ecological assessment for Alzheimer’s disease
  121. Brain-Penetrating Angiotensin-Converting Enzyme Inhibitors and Cognitive Change in Patients with Dementia due to Alzheimer's Disease
  122. P2‐024: PHARMACOGENETICS OF BRAIN‐PENETRATING ANGIOTENSIN‐CONVERTING ENZYME INHIBITORS IN DEMENTIA DUE TO ALZHEIMER'S DISEASE
  123. P2‐025: PHARMACOGENETICS OF CHOLESTEROL‐LOWERING DRUGS IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE
  124. P3‐333: RISK FACTORS FOR COGNITIVE CHANGE IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE FROM SÃO PAULO, BRAZIL
  125. Caregiver awareness of cerebrovascular risk of patients with dementia due to Alzheimer's disease in São Paulo, Brazil
  126. Abstracts from the 29th CINP World Congress of Neuropsychopharmacology, Vancouver, Canada, 22–26 June 2014
  127. Risk Factors for Cognitive Change in Patients with Dementia Due to Alzheimer’s Disease (P5.210)
  128. Pharmacogenetics of Lipid Metabolism Modulators in Patients with Dementia Due to Alzheimer’s Disease (P5.223)
  129. Risk factors for age at onset of dementia due to Alzheimer's disease in a sample of patients with low mean schooling from São Paulo, Brazil
  130. 2013 Reviewer Acknowledgement
  131. Assessment of risk factors for earlier onset of sporadic Alzheimer′s disease dementia
  132. Educational bias in the assessment of severe dementia: Brazilian cutoffs for severe Mini-Mental State Examination
  133. Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease
  134. Cognitive Impairment in Fibromyalgia
  135. Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from São Paulo, Brazil (IN6-1.009)
  136. Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from São Paulo, Brazil (P07.136)
  137. Communicating with the non-dominant hemisphere: Implications for neurological rehabilitation
  138. Normal pressure hydrocephalus in the spectrum of neurological complications of systemic lupus erythematosus
  139. A patient with primary progressive aphasia developing dementia due to Alzheimer's disease
  140. Impact of Cerebrovascular Risk Factors over Age of Onset of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from Sao Paulo, Brazil (P04.201)
  141. 2012 Annual Meeting Sunday, October 7, 2012 Poster Session Abstracts
  142. A topographic study on the evaluation of speech and language in the acute phase of a first stroke
  143. P1‐453: Functional independence and tests of cognitive assessment in patients with Alzheimer's disease
  144. P2‐153: Impact of cardiovascular risk factors over age of Alzheimer's disease onset in patients with low schooling
  145. P3‐260: Impact of schooling and cardiovascular risk factors over the rate of progression of Alzheimer's disease
  146. Twenty-first Meeting of the European Neurological Society 28–31 May, 2011
  147. Global aphasia as a predictor of mortality in the acute phase of a first stroke
  148. Semantic aphasia as a sole manifestation of acute stroke
  149. Preliminary topographic diagnosis of ischemic brain injuries according to speech and language disorders
  150. Short-term prognosis for speech and language in first stroke patients
  151. Hypoglossal nerve palsy as the sole manifestation of spontaneous internal carotid artery dissection
  152. Author Index
  153. Abstracts
  154. 0661 Primitive Neuroectodermal Tumor of the brain presenting with late spinal cord dissemination after surgical treatment and complementary radiotherapy and chemotherapy
  155. 1499 Trends on the use of complementary exams in modern day neurology: how to teach the patient about the tools actually needed for the investigation without conflicting knowledge with popular wisdom